Ann: Share Purchase Plan Booklet & Option Prospectus, page-32

15 treated and 15 (placebo or standard of care) is a pretty small sample.

It's too small for complete commercialisation, but not (IMO) for a partner. Plenty can be derived from 30 people - the key will be in the variance. If Cymerus cells are as consistent as Ross loves to tell us, then this should be relatively simple to show.

in my opinion there will never be a big pharma partner that is stupid like a retail shareholder can be stupid
As an example, Novartis signed a partnership with Mesoblast with $25M upfront in cash, $25M in equity based on the results of a 12 person Covid-19 trial. Important to note MSB never received the cash because shortly after they snatched defeat from the jaws of victory by failing the P3 a month later. While Novartis didn't outlay $50M, they invested probably $10-15M (USD) in organising a non-covid ARDS trial and due diligence.

If you've already got access to the wound from outside there almost certainly should be better things to put on the wound than something as crude as an entire cell
Right now you're just being a contrarian for the sake of being a contrarian. Do some reading on diabetic wounds. These aren't paper cuts - they're chronic, open wounds that struggle to heal. Just putting stuff on it doesn't cut it - you need something to encourage to tissue to regenerate. There is good pre-clinical data that our cells work. The other thing I'll add is that the dearth in realistic alternatives for patients creates a unique opportunity for a big pharma partner. A partner with a good relationship with the TGA could probably convince them for provisional approval if the P1 results are as strong as the initial 6 patients indicate and safety does not prove to be an issue. How much would they have to pay up front to license this from us? $20M? $10M?